Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: A cluster analysis

International Journal of COPD

Volumn 9, Issue , 2014, Pages 457-468

  DiSantostefano, Rachael L ^a   Li, Hao ^a   Hinds, David ^a   Galkin, Dmitry V ^a   Rubin, David B ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cluster analysis; Inhaled corticosteroids; Long acting 2 agonists; Pneumonia

Indexed keywords

ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINOCICEPTIVE AGENT; ANTIRHEUMATIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; CORTICOSTEROID; DIURETIC AGENT; FLUTICASONE FUROATE PLUS VILANTEROL; INFLUENZA VACCINE; LONG ACTING DRUG; VILANTEROL;

ADULT; AGED; ALGORITHM; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PATIENT CARE; PNEUMONIA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK MANAGEMENT; TREATMENT OUTCOME;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CLUSTER ANALYSIS; INHALED CORTICOSTEROIDS; LONG-ACTING Β2-AGONISTS; PNEUMONIA;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; CLUSTER ANALYSIS; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; LUNG; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84900408808     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S60498     Document Type: Article

References (31)

1. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006;28(2):346-351.
2. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124-1133.
3. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826.
4. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173(7):736-743.
5. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210-223.
6. BREO™ ELLIPTA™ (fluticasone furoate/vilanterol inhalation powder) for treatment of chronic obstructive pulmonary disease. NDA204275. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM347931.pdf. Accessed January 6, 2014.
7. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
8. Breiman L. Classification and Regression Trees. New York, NY, USA: Chapman and Hall; 1983.
9. Therneau T, Atkinson B, Ripley B. RPART: Recursive Partitioning. R package version 4.0-1. 2012. Available from: http://cran.r-project.org/web/packages/rpart/index.html. Accessed January 6, 2014.
10. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728-735.
11. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641-647.
12. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010;16(2): 118-122.
13. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 1128-1138.
14. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661-666.
15. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013;68(2):171-176.
16. Chou FH, Tsai KY, Chou YM. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study. J Psychiatr Res. 2013;47(4):460-146.
17. Quint JK, Brown JS. Weighing up risk factors for pneumonia: the role of mental illness and benzodiazepine use. Thorax. 2013;68(2): 121-122.
18. Hanania NA, Müllerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604-611.
19. Papaioannou AI, Bartziokas K, Tsikrika S, et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J. 2013;41(4):815-823.
20. Rushnak MJ, Leevy CM. Effect of diazepam on the lower esophageal sphincter. A double-blind controlled study. Am J Gastroenterol. 1980;73(2):127-130.
21. Vozoris NT, Fischer HD, Wang X, Anderson GM, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3): 183-192.
22. Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(2):163-170.
23. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc. 2011;59(10):1899-1907.
24. Sanders RD, Degos V, Young WL. Cerebral perfusion under pressure: is the autoregulatory 'plateau' a level playing field for all? Anaesthesia. 2011;66(11):968-972.
25. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4): 347-365.
26. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older - United States, 2013. MMWR Surveill Summ. 2013;62 Suppl 1:1.
27. Weatherall M, Shirtcliffe P, Travers J, Beasley R. Use of cluster analysis to define COPD phenotypes. Eur Respir J. 2010;36(3):472-474.
28. Travers J, Weatherall M, Fingleton J, Beasley R. Towards individualised medicine for airways disease: identifying clinical phenotype groups. Eur Respir J. 2012;39(4):1033-1034.
29. Burgel PR, Roche N, Paillasseur JL, et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J. 2012;40(2):495-496.
30. Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430-437.
31. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax. 2010;65(10):884-890.